In the last trading session, 2.85 million Intellia Therapeutics Inc (NASDAQ:NTLA) shares changed hands as the company’s beta touched 2.32. With the company’s per share price at $8.20 changed hands at -$0.28 or -3.30% during last session, the market valuation stood at $848.85M. NTLA’s last price was a discount, traded about -243.66% off its 52-week high of $28.18. The share price had its 52-week low at $5.90, which suggests the last value was 28.05% up since then. When we look at Intellia Therapeutics Inc’s average trading volume, we note the 10-day average is 2.8 million shares, with the 3-month average coming to 3.39 million.
Analysts gave the Intellia Therapeutics Inc (NTLA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.64. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NTLA as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Instantly NTLA was in red as seen at the end of in last trading. With action -1.32%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -29.67%, with the 5-day performance at -1.32% in the red. However, in the 30-day time frame, Intellia Therapeutics Inc (NASDAQ:NTLA) is 1.61% up. Looking at the short shares, we see there were 28.51 million shares sold at short interest cover period of 7.57 days.
The consensus price target for the stock as assigned by Wall Street analysts is 26, meaning bulls need an upside of 68.46% from its current market value. According to analyst projections, NTLA’s forecast low is 9 with 60 as the target high. To hit the forecast high, the stock’s price needs a -631.71% plunge from its current level, while the stock would need to soar -9.76% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -20.04%. The 2025 estimates are for Intellia Therapeutics Inc earnings to increase by 10.69%, but the outlook for the next 5-year period is at 23.52% per year.
NTLA Dividends
Intellia Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.05% of Intellia Therapeutics Inc shares while 94.56% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.59%. There are 94.56% institutions holding the Intellia Therapeutics Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 11.9575% of the shares, roughly 11.6 million NTLA shares worth $259.51 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.897% or 9.6 million shares worth $214.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were ARK ETF Trust-ARK Innovation ETF and SMALLCAP WORLD FUND INC . With 8.7 shares estimated at $71.37 million under it, the former controlled 8.41% of total outstanding shares. On the other hand, SMALLCAP WORLD FUND INC held about 3.65% of the shares, roughly 3.78 shares worth around $30.99 million.
